Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Blood tests could predict infections in ICU patients

NCT ID NCT02638779

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This completed study looked at how the immune system is weakened after septic shock, severe trauma, burns, or major surgery. Researchers took blood samples from 552 patients and healthy volunteers to measure immune function. The goal was to find better ways to predict and manage infections in critically ill patients.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this study could provide tools to predict and manage infections in critically ill patients.
What could go wrong
This is an observational study, not a treatment trial. It may not lead to direct patient benefits.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

552 people

The number who actually took part.

Started

Dec 2015

Finished

Jun 2018

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion criteria for patients * Patient or next of kin having been informed of the conditions of the study and having signed the informed consent form * Patient hospitalized for : * Septic shock * Severe trauma (including severe burn) * Major surgery Inclusion criteria for healthy volunteers * Normal clinical examination * Signed informed consent form * Person with social security insurance Exclusion criteria for patients * Patient with severe neutropenia (neutrophil count \<0.5 g/l) * Patients receiving immunosuppressive therapy * Patients receiving corticosteroids (IV or Per os) * Use of therapeutic antibodies * Hematological disease under treatment, or treated within 5 years before inclusion * End of chemotherapy within the 6 months prior to inclusion * Patient with innate or acquired immune deficiency (for example severe combined immunodeficiency, HIV or AIDS, any stage) * Patients for whom a care limitation was pronounced at time of enrolment * Anticipated length of stay before discharge from the ICU is estimated at less than 48 hours * Participation in an intervention study * Extra-corporeal circulation in the month preceding inclusion in case of cardiac surgery * Pregnant or breastfeeding women * Patient with no social security insurance, with restricted liberty or under legal protection Exclusion criteria for healthy volunteers * Person with an infectious syndrome during the last 90 days * Extreme physical stress within the last week * Person having received within the last 90 days, a treatment based on * Antivirals * Antibiotics * Antiparasitics * Antifungics * Person having received within the last 15 days, a treatment based on non-steroidal anti-inflammatory drugs (NSAIDs) * Person having received within the last 24 months, a treatment based on * Immunosuppressive therapy * Corticosteroids (IV or Per os) * Therapeutic antibodies * Chemotherapy * History of : * innate or acquired immune deficiency * Hematological disease * Solid tumor * Severe chronic disease * Surgery or hospitalization within the last 2 years * Pregnancy within the last year * Participation to a phase I clinical assay during the last year * Pregnant or breastfeeding women * Person with restricted liberty or under legal protection

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Major surgery are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Service d'Anesthésie Réanimation - Hôpital Edouard Herriot

    Lyon, 69437, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.